Search

BACKGROUND: Obstructive sleep apnea is a disorder characterized by recurrent obstruction of the upper airways during sleep. The high prevalence of this disease led to proposed new strategies based on the home evaluation and management of patients. OBJECTIVE: To compare home unattended portable monitoring and automatic CPAP titration with attended in-laboratory analysis, in a sample of patients with high risk for moderate to severe obstructive sleep apnea. METHODS: We enrolled 131 subjects, who were randomly divided into 2 groups: the home group (n = 66) was diagnosed and titrated at home; the laboratory group (n = 65) was analyzed in the sleep laboratory of our hospital. Diagnostic evaluations were carried out with portable monitoring at home, and with polysomnography in the sleep laboratory. Titration of CPAP was performed with the same automatic CPAP device in both groups. RESULTS: At the end of the study, 13 (19%) subjects had dropped out of the home group, and 9 (14%) of the laboratory group (P = .50). There were no significant differences among groups in both baseline and with-CPAP values of apneahypopnea index, oxygen desaturation index, and total sleep time with SpO2 below 90%. In the home group, the therapeutic pressure values reached at the end of each unattended home titration night were similar. CONCLUSIONS: A home diagnosis and titration approach should be considered in a subset of patients with obstructive sleep apnea. A single unattended titration night is sufficient to determine the therapeutic pressure. [ABSTRACT FROM AUTHOR]

Background & Aims: We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. Methods: In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child–Pugh classes B7–C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was prevention of PVT. Radiologists and hepatologists that assessed outcomes were blinded to group assignments. Analysis was by intention to treat. Results: At 48 weeks, none of the patients in the enoxaparin group had developed PVT, compared with 6 of 36 (16.6%) controls (P = .025). At 96 weeks, no patient developed PVT in the enoxaparin group, compared with 10 of 36 (27.7%) controls (P = .001). At the end of the follow-up period, 8.8% of patients in the enoxaparin group and 27.7% of controls developed PVT (P = .048). The actuarial probability of PVT was lower in the enoxaparin group (P = .006). Liver decompensation was less frequent among patients given enoxaparin (11.7%) than controls (59.4%) (P < .0001); overall values were 38.2% vs 83.0%, respectively (P < .0001). The actuarial probability of liver decompensation was lower in the enoxaparin group (P < .0001). Eight patients in the enoxaparin group and 13 controls died. The actuarial probability of survival was higher in the enoxaparin group (P = .020). No relevant side effects or hemorrhagic events were reported. Conclusions: In a small randomized controlled trial, a 12-month course of enoxaparin was safe and effective in preventing PVT in patients with cirrhosis and a Child–Pugh score of 7–10. Enoxaparin appeared to delay the occurrence of hepatic decompensation and to improve survival. www.isrctn.>org: ISRCTN32383354; www.clinicaltrialsregister.eu: EudraCT2007-007890-22. [Copyright &y& Elsevier]

More than 60% of the 1,700 infectious diseases that affect human come from animals and zoonotic pandemics, after starting from sporadic phenomena limited to rural areas, have become a global emergency. The repeated and frequent zoonotic outbreaks such as the most recent COVID-19 pandemic can be attributed also to human activities. In particular, the creation of enormous intensive domestic animal farms, the indiscriminate use of antibiotics, the destruction of forests, the consumption of the meat of wild animals and the illegal animal trade are all factors causing the insurgence and the transmission of zoonotic diseases from animals to humans. The purpose of this study was to explore the knowledge of the One Health concept including the zoonotic risk potentially derived from illegally traded pet animals and wildlife among adolescents in 6 different countries (Italy, Austria, Slovenia, Germany, Mauritius, and Japan). A representative sample of 656 students was recruited and all participants took an anonymous questionnaire. Data were analyzed by ANOVAs to estimate the prevalence of correct health prevention behaviors and to identify the influential factors for these behaviors. After two theoretical-practical lectures, the same anonymous questionnaire was administered for the second time in order to assess the efficacy of the program. The proportion of students who did not know that many diseases affecting humans come from animals is 28.96% while 32.16% of them did not know what a zoonosis is. The circularity of the One Health concept related to the transmission of diseases from animals to humans and vice-versa is not understood from a large prevalence of the adolescents with 31.40 and 59.91% of wrong responses, respectively. Furthermore, rabies is not considered as a dangerous disease by 23.02% of the adolescents. After two theoretical-practical classroom sessions, the correct answers improved to 21.92% according to the different question. More than a third of the student cohort investigated showed a profound ignorance of the zoonotic risks and a poor understanding of the One Health concept. The authors believe that the teaching of health prevention with a One Health approach and a practical training should be included in every school curriculum., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Zucca, Rossmann, Dodic, Ramma, Matsushima, Seet, Holtze, Bremini, Fischinger, Morosetti, Sitzia, Furlani, Greco, Meddi, Zambotto, Meo, Pulcini, Palei and Zamaro.)

Illegal animal trade (pet, wildlife, animal products, etc.) is an example of transnational organized crime (T.O.C.) that generates a large business with huge profit margins. This criminal activity causes several negative effects on human health (zoonoses), animal health and welfare, market protection, consumer fraud and may be used as tool of agro/bio-terrorism. Illegal animal trade can facilitate the spread of zoonoses that are defined as diseases and infections that are transmitted by vertebrate animals to man. Humans are affected by more than 1,700 known pathogens: 60% of existing human infectious diseases are zoonotic and at least 75% of emerging infectious diseases of humans have an animal origin and 72% of zoonoses originate from wildlife or exotic animals. The Bio-Crime Project was developed in 2017 by Friuli Venezia Giulia Region (Italy) and Land Carinthia (Austria) together with other public institutions to combat illegal animal trade and to reduce the risk of disease transmission from animals to humans. Project partners agreed that a multi-agency approach was required to tackle the illegal animal trade that was high value, easy to undertake and transnational crime. The Bio-crime model of cross-border cooperation introduces the novel approach of replicating the cooperative framework given by the triad of Veterinary Public Health, Justice and Law Enforcements/Customs across borders using the International Police and Custom Cooperation Centres (IPCCCs) as a connection link among public entities of the neighbor countries. This model has been recognized as a best practice at European level because it can be easily replicated and scaled up without any supplementary cost for Member States., (Copyright © 2020 Zucca, Rossmann, Osorio, Karem, De Benedictis, Haißl, De Franceschi, Calligaris, Kohlweiß, Meddi, Gabrutsch, Mairitsch, Greco, Furlani, Maggio, Tolomei, Bremini, Fischinger, Zambotto, Wagner, Millard, Palei and Zamaro.)

In 2005 the Autonomous Province of Bolzano implemented a BVD-Virus control programme by testing all newborn calves for Bovine Viral Diarrhoea Virus (BVDV) antigen by analysing ear notch samples. In eradication programs between November 2005 and October 2010 a total of 344,108 newborn calves were ear notch sampled and analysed for BVDV by an antigen ELISA detecting the E(rns) (HerdCheck BVDV Antigen/Serum Plus, Idexx Laboratories, Switzerland). The tissue samples were collected during calf ear tagging (within the first 20 days of life) using two sampling devices (TypiFix-System, Agrobiogen GmbH [Germany] and Allflex [France]). 0.4% (1400) of the collected samples showed a positive result, and of these, 583 calves were subjected to a follow-up examination, analysing the samples again by ELISA as well blood samples by Reverse transcriptase-PCR. Blood samples were also collected from the dam, if still present on the farm by the time of sampling. These results suggest that a BVDV control programme testing all newborn calves sampled for BVDV antigen by analysing an ear notch sample in principle is practicable. However, due to the low positive predictive value (75%) of the E(rns)-ELISA used, not all persistently infected calves can be detected.